JNJ vs REPL

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

Replimune (REPL) maintains a high-conviction, high-risk, high-reward profile, with its score slightly increasing due to recent positive developments. The previous analysis heavily anticipated pivotal RP1 data, and an update from the Phase 3 IGNYTE trial in anti-PD1 failed melanoma patients showing a 32% ORR (Mar 22, 2026) provides strong preliminary validation. This significantly de-risks the prim...